Consistent with our present results, many other studies have also demonstrated that RAP2 functions as an oncogene, and RAP2 is notably upregulated in human tumour samples and cancer cell lines, including prostate cancer[15], follicular thyroid cancer[29], lung cancer[30] and breast cancer[31]. Here, RAP2A is linked to prostate carcinoma.